Viking Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
Ticker: VKTX · Form: 10-Q · Filed: Apr 25, 2024 · CIK: 1607678
Sentiment: neutral
Topics: Viking Therapeutics, VKTX, 10-Q, Pharmaceuticals, Financials
Related Tickers: VKTX
TL;DR
<b>Viking Therapeutics filed its Q1 2024 10-Q, detailing financial performance and operational updates.</b>
AI Summary
Viking Therapeutics, Inc. (VKTX) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. Viking Therapeutics, Inc. filed a 10-Q report for the quarter ended March 31, 2024. The filing details financial information and business operations for the specified period. Key dates and events related to equity incentive plans and stock offerings are referenced. The company's fiscal year ends on December 31st. Viking Therapeutics is in the Pharmaceutical Preparations industry (SIC code 2834).
Why It Matters
For investors and stakeholders tracking Viking Therapeutics, Inc., this filing contains several important signals. This 10-Q filing provides investors with the latest financial statements and management's discussion of results for Viking Therapeutics, crucial for understanding the company's current financial health and strategic direction. The detailed information on equity plans, stock offerings, and financial instruments helps stakeholders assess potential dilution, capital structure, and investment risks.
Risk Assessment
Risk Level: medium — Viking Therapeutics, Inc. shows moderate risk based on this filing. The company operates in the highly competitive pharmaceutical sector, facing risks related to drug development, clinical trials, regulatory approvals, and market adoption, as indicated by the nature of its business (Pharmaceutical Preparations).
Analyst Insight
Monitor upcoming clinical trial results and regulatory updates for Viking Therapeutics' drug candidates, as these will be key drivers of future stock performance.
Key Numbers
- 2024-03-31 — Reporting Period End Date (10-Q filing)
- 2023-12-31 — Previous Year End Date (Referenced in filing)
- 2024-01-01 — Start Date for Performance-Based Restricted Stock Units (vktx:PerformanceBasedRestrictedStockUnitsMember)
- 2014-02-01 — Start Date for Equity Incentive Plan (vktx:TwoThousandFourteenEquityIncentivePlanMember)
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Filer name
- 0000950170-24-047833 (other) — Accession Number
- 20240331 (date) — Period of Report
- 20240425 (date) — Filed as of date
- 0001607678 (other) — Central Index Key
- 2834 (other) — Standard Industrial Classification (Pharmaceutical Preparations)
- 9920 PACIFIC HEIGHTS BLVD, SUITE 350 (address) — Business Address
- SAN DIEGO (location) — Business Address City
FAQ
When did Viking Therapeutics, Inc. file this 10-Q?
Viking Therapeutics, Inc. filed this Quarterly Report (10-Q) with the SEC on April 25, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by Viking Therapeutics, Inc. (VKTX).
Where can I read the original 10-Q filing from Viking Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Viking Therapeutics, Inc..
What are the key takeaways from Viking Therapeutics, Inc.'s 10-Q?
Viking Therapeutics, Inc. filed this 10-Q on April 25, 2024. Key takeaways: Viking Therapeutics, Inc. filed a 10-Q report for the quarter ended March 31, 2024.. The filing details financial information and business operations for the specified period.. Key dates and events related to equity incentive plans and stock offerings are referenced..
Is Viking Therapeutics, Inc. a risky investment based on this filing?
Based on this 10-Q, Viking Therapeutics, Inc. presents a moderate-risk profile. The company operates in the highly competitive pharmaceutical sector, facing risks related to drug development, clinical trials, regulatory approvals, and market adoption, as indicated by the nature of its business (Pharmaceutical Preparations).
What should investors do after reading Viking Therapeutics, Inc.'s 10-Q?
Monitor upcoming clinical trial results and regulatory updates for Viking Therapeutics' drug candidates, as these will be key drivers of future stock performance. The overall sentiment from this filing is neutral.
Risk Factors
- Regulatory Risks [high — regulatory]: The company is subject to extensive government regulation, including the FDA, which can impact drug development, approval, and marketing.
- Market Competition [high — market]: The pharmaceutical market is highly competitive, with many companies developing drugs for similar conditions.
- Clinical Trial Risks [high — operational]: Clinical trials are expensive, time-consuming, and have uncertain outcomes, with a high failure rate.
- Funding Requirements [medium — financial]: The company requires significant capital for research, development, and commercialization, and may need to raise additional funds.
Key Dates
- 2024-03-31: Quarterly Period End — Reporting period for the 10-Q filing.
- 2024-04-25: Filing Date — Date the 10-Q was officially filed with the SEC.
Filing Stats: 4,401 words · 18 min read · ~15 pages · Grade level 17.7 · Accepted 2024-04-24 20:42:21
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20240331.htm (10-Q) — 1711KB
- vktx-ex31_1.htm (EX-31.1) — 15KB
- vktx-ex31_2.htm (EX-31.2) — 15KB
- vktx-ex32_1.htm (EX-32.1) — 11KB
- 0000950170-24-047833.txt ( ) — 7109KB
- vktx-20240331.xsd (EX-101.SCH) — 968KB
- vktx-20240331_htm.xml (XML) — 1214KB
Notes to Consolidated Financial Statements (unaudited)
Notes to Consolidated Financial Statements (unaudited) 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.
Controls and Procedures
Controls and Procedures 24 Part II. OTHER INFORMATION 26 Item 1.
Legal Proceedings
Legal Proceedings 26 Item 1A.
Risk Factors
Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 61 Item 3. Defaults Upon Senior Securities 61 Item 4. Mine Safety Disclosures 61 Item 5. Other Information 62 Item 6. Exhibits 63
FINANCI AL INFORMATION
PART I. FINANCI AL INFORMATION
Financ ial Statements
Item 1. Financ ial Statements Viking Therapeutics, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) March 31, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 195,579 $ 55,516 Short-term investments – available-for-sale 767,397 306,563 Prepaid clinical trial and preclinical study costs 2,716 2,624 Prepaid expenses and other current assets 643 2,522 Total current assets 966,335 367,225 Right-of-use assets 1,052 1,126 Deferred financing costs 98 106 Deposits 33 33 Total assets $ 967,518 $ 368,490 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 5,225 $ 7,512 Other accrued liabilities 27,220 11,299 Lease liability, current 329 324 Total current liabilities 32,774 19,135 Lease liability, net of current portion 852 936 Total long-term liabilities 852 936 Total liabilities 33,626 20,071 Commitments and contingencies ( Note 7 ) Stockholders' equity: Preferred stock, $ 0.00001 par value: 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock, $ 0.00001 par value: 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 110,228,869 shares issued and outstanding at March 31, 2024 and 100,113,770 shares issued and outstanding at December 31, 2023 1 1 Treasury stock at cost, no shares at March 31, 2024 and 2,193,251 shares at December 31, 2023 — ( 6,795 ) Additional paid-in capital 1,340,789 733,546 Accumulated deficit ( 405,299 ) ( 377,944 ) Accumulated other comprehensive loss ( 1,599 ) ( 389 ) Total stockholders' equity 933,892 348,419 Total liabilities and stockholders' equity $ 967,518 $ 368,490 See accompanying notes to the unaudited consolidated financial statemen